These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20637614)

  • 1. Identification of N-(2-(azepan-1-yl)-2-phenylethyl)-benzenesulfonamides as novel inhibitors of GlyT1.
    Varnes JG; Forst JM; Hoerter TN; Holmquist CR; Wilkins DE; Tian G; Jonak G; Wang X; Potts WM; Wood MW; Alhambra C; Brugel TA; Albert JS
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4878-81. PubMed ID: 20637614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitors.
    Thomson JL; Blackaby WP; Jennings AS; Goodacre SC; Pike A; Thomas S; Brown TA; Smith A; Pillai G; Street LJ; Lewis RT
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2235-9. PubMed ID: 19318248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides.
    Lindsley CW; Zhao Z; Leister WH; O'Brien J; Lemaire W; Williams DL; Chen TB; Chang RS; Burno M; Jacobson MA; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Tsou NN; Duggan ME; Conn PJ; Hartman GD
    ChemMedChem; 2006 Aug; 1(8):807-11. PubMed ID: 16902933
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors.
    Zhao Z; Leister WH; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Hartman GD; Lindsley CW; Wolkenberg SE
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1488-91. PubMed ID: 19179073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies.
    Zeng Z; O'Brien JA; Lemaire W; O'Malley SS; Miller PJ; Zhao Z; Wallace MA; Raab C; Lindsley CW; Sur C; Williams DL
    Nucl Med Biol; 2008 Apr; 35(3):315-25. PubMed ID: 18355687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.
    Wolkenberg SE; Zhao Z; Wisnoski DD; Leister WH; O'Brien J; Lemaire W; Williams DL; Jacobson MA; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Gibson C; Ma BK; Polsky-Fisher SL; Lindsley CW; Hartman GD
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1492-5. PubMed ID: 19181525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and SAR studies of novel GlyT1 inhibitors.
    Walter MW; Hoffman BJ; Gordon K; Johnson K; Love P; Jones M; Man T; Phebus L; Reel JK; Rudyk HC; Shannon H; Svensson K; Yu H; Valli MJ; Porter WJ
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5233-8. PubMed ID: 17629697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,3-diaminopropan-2-ol sulfonamides as potent and selective inhibitors of the glycine transporter type 1.
    Rahman SS; Coulton S; Herdon HJ; Joiner GF; Jin J; Porter RA
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1741-5. PubMed ID: 17234406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of (4H-1,2,4-triazol-4-yl)isoquinoline derivatives as selective glycine transporter 1 inhibitors.
    Sugane T; Tobe T; Hamaguchi W; Shimada I; Maeno K; Miyata J; Suzuki T; Kimizuka T; Morita T; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2012 Jan; 20(1):34-41. PubMed ID: 22177408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 3-biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as novel glycine transporter 1 inhibitors.
    Sugane T; Tobe T; Hamaguchi W; Shimada I; Maeno K; Miyata J; Suzuki T; Kimizuka T; Kohara A; Morita T; Doihara H; Saita K; Aota M; Furutani M; Shimada Y; Hamada N; Sakamoto S; Tsukamoto S
    J Med Chem; 2011 Jan; 54(1):387-91. PubMed ID: 21141920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter.
    Lowe JA; Hou X; Schmidt C; David Tingley F; McHardy S; Kalman M; Deninno S; Sanner M; Ward K; Lebel L; Tunucci D; Valentine J; Bronk BS; Schaeffer E
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2974-6. PubMed ID: 19410451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides.
    Zhao Z; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Sur C; Pettibone DJ; Tiller PR; Smith S; Hartman GD; Wolkenberg SE; Lindsley CW
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5968-72. PubMed ID: 16987662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres.
    Sheffler DJ; Nedelcovych MT; Williams R; Turner SC; Duerk BB; Robbins MR; Jadhav SB; Niswender CM; Jones CK; Conn PJ; Daniels RN; Lindsley CW
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1062-6. PubMed ID: 24462664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors.
    Pinard E; Ceccarelli SM; Stalder H; Alberati D
    Bioorg Med Chem Lett; 2006 Jan; 16(2):349-53. PubMed ID: 16246557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based optimization of novel azepane derivatives as PKB inhibitors.
    Breitenlechner CB; Wegge T; Berillon L; Graul K; Marzenell K; Friebe WG; Thomas U; Schumacher R; Huber R; Engh RA; Masjost B
    J Med Chem; 2004 Mar; 47(6):1375-90. PubMed ID: 14998327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
    Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose.
    Uslaner JM; Drott JT; Sharik SS; Theberge CR; Sur C; Zeng Z; Williams DL; Hutson PH
    Behav Brain Res; 2010 Feb; 207(1):37-43. PubMed ID: 19799936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
    Perry KW; Falcone JF; Fell MJ; Ryder JW; Yu H; Love PL; Katner J; Gordon KD; Wade MR; Man T; Nomikos GG; Phebus LA; Cauvin AJ; Johnson KW; Jones CK; Hoffmann BJ; Sandusky GE; Walter MW; Porter WJ; Yang L; Merchant KM; Shannon HE; Svensson KA
    Neuropharmacology; 2008 Oct; 55(5):743-54. PubMed ID: 18602930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.
    Pinard E; Alberati D; Borroni E; Fischer H; Hainzl D; Jolidon S; Moreau JL; Narquizian R; Nettekoven M; Norcross RD; Stalder H; Thomas AW
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5134-9. PubMed ID: 18752953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.